腹腔镜肝切除从创新到精通:4个欧洲专科中心2238例围术期与肿瘤学结局
该研究评估2000至2015年4个欧洲专科中心2238例腹腔镜肝切除患者,分析技术方法、围术期与肿瘤学结局及实践演变。腹腔镜肝切除比例从2000年5%升至2015年43%,失血量、手术时间和中转率随时间显著改善。肝细胞癌和结直肠癌肝转移的5年总生存率分别为73%和54%。
要点
- 腹腔镜肝切除比例从2000年5%增至2015年43%,纯腹腔镜占98.3%。
- 楔形切除最常见,后期稳定在约53%;大范围肝切除增至约16%。
- 肝细胞癌5年总生存率73%,结直肠癌肝转移为54%。
核心结论
- 腹腔镜肝切除引入后需长期实施过程以实现标准化、技术精通并取得良好围术期与安全肿瘤学结局。
研究设计与样本
- 回顾性评估2000至2015年4个欧洲专科中心2238例腹腔镜肝切除患者的人口学、适应证、术中、围术期和肿瘤学结局,并分析实践与结局随时间趋势。
主要发现
- 腹腔镜肝切除年度比例从2000年5%升至2015年43%,纯腹腔镜占98.3%。
- 楔形切除最常见,初期占主导后下降并稳定在约53%;大范围肝切除初期少见后增至约16%稳定。
- 后上段切除共410例,随时间增多,2015年占比最高达26%。
- 失血量、手术时间和中转率随时间显著改善。
- 肝细胞癌5年总生存率73%、无复发生存率50%;结直肠癌肝转移5年总生存率54%、无复发生存率37%。
临床怎么用
- 专科中心开展腹腔镜肝切除时,楔形切除和大范围肝切除比例随时间趋于稳定,后上段切除比例增加。
- 关注失血量、手术时间和中转率等围术期指标,随时间推移可显著改善。
- 肝细胞癌和结直肠癌肝转移患者腹腔镜肝切除可获得相应5年生存和复发结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First seen as an innovation for select patients, laparoscopic liver resection (LLR) has evolved since its introduction, resulting in worldwide use. Despite this, it is still limited mainly to referral centers. The aim of this study was to evaluate a large cohort undergoing LLR from 2000 to 2015, focusing on the technical approaches, perioperative and oncologic outcomes, and evolution of practice over time. STUDY DESIGN: The demographics and indications, intraoperative, perioperative, and oncologic outcomes of 2,238 patients were evaluated. Trends in practice and outcomes over time were assessed. RESULTS: The percentage of LLR performed yearly has increased from 5% in 2000 to 43% in 2015. Pure laparoscopy was used in 98.3% of cases. Wedge resections were the most common operation; they were predominant at the beginning of LLR and then decreased and remained steady at approximately 53%. Major hepatectomies were initially uncommon, then increased and reached a stable level at approximately 16%. Overall, 410 patients underwent resection in the posterosuperior segments; these were more frequent with time, and the highest percentage was in 2015 (26%). Blood loss, operative time, and conversion rate improved significantly with time. The 5-year overall survival rates were 73% and 54% for hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM), respectively. The 5-year, recurrence-free survival rates were 50% and 37% for HCC and CRLM, respectively. CONCLUSIONS: Since laparoscopy was introduced, a long implementation process has been necessary to allow for standardization and improvement in surgical care, mastery of the technique, and the ability to obtain good perioperative results with safe oncologic outcomes.
引用
- Berardi G, Van Cleven S, Fretland ÅA, et al. Evolution of Laparoscopic Liver Surgery from Innovation to Implementation to Mastery: Perioperative and Oncologic Outcomes of 2,238 Patients from 4 European Specialized Centers. J Am Coll Surg. 2017. PMID: 28838869. doi:10.1016/j.jamcollsurg.2017.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。